IDNA - Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease

• Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease.
• As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release.
• Blarcamesine likely scavenges peroxynitrite.  Its main oxidation product, butyrolactone, converts some of the remaining peroxynitrite into nitrate.
• Blarcamesine reverses some of the damage done to the brain by peroxynitrite by acting as an antioxidant and through the de-nitration of critical receptors, transport systems, and enzymes.
• Phase 2b/3 trial results for blarcamesine may be available as soon as the end of this year. If the results are positive, the FDA will likely grant the drug accelerated approval.

For further details see: